Chronic conditions resources

This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).

This factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.

This factsheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).

This factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.

This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).

Australian Government response to the Senate Community Affairs References Committee inquiry into support for Australia’s thalidomide survivors

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.

This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.

This document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for paroxysmal nocturnal haemoglobinuria for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this document to certify their patient's meningococcal vaccination status when applying or reapplying for eculizumab through the Life Saving Drugs Program.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.